JP2024504392A - Ａｔ－５２７ヘミ硫酸塩の有利な形態 - Google Patents

Ａｔ－５２７ヘミ硫酸塩の有利な形態 Download PDF

Info

Publication number
JP2024504392A
JP2024504392A JP2023544450A JP2023544450A JP2024504392A JP 2024504392 A JP2024504392 A JP 2024504392A JP 2023544450 A JP2023544450 A JP 2023544450A JP 2023544450 A JP2023544450 A JP 2023544450A JP 2024504392 A JP2024504392 A JP 2024504392A
Authority
JP
Japan
Prior art keywords
compound
form iii
pharmaceutical composition
virus
solid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504392A5 (https=
Inventor
アデル ムーサ
Original Assignee
アテア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アテア ファーマシューティカルズ， インコーポレイテッド filed Critical アテア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024504392A publication Critical patent/JP2024504392A/ja
Publication of JP2024504392A5 publication Critical patent/JP2024504392A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP2023544450A 2021-01-26 2022-01-26 Ａｔ－５２７ヘミ硫酸塩の有利な形態 Pending JP2024504392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141789P 2021-01-26 2021-01-26
US63/141,789 2021-01-26
PCT/US2022/013953 WO2022164941A1 (en) 2021-01-26 2022-01-26 Advantageous morphic form of at-527 hemi-sulfate salt

Publications (2)

Publication Number Publication Date
JP2024504392A true JP2024504392A (ja) 2024-01-31
JP2024504392A5 JP2024504392A5 (https=) 2025-01-29

Family

ID=82653876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544450A Pending JP2024504392A (ja) 2021-01-26 2022-01-26 Ａｔ－５２７ヘミ硫酸塩の有利な形態

Country Status (12)

Country Link
US (2) US20230365611A1 (https=)
EP (1) EP4284389A4 (https=)
JP (1) JP2024504392A (https=)
KR (1) KR20230135635A (https=)
CN (1) CN116744939A (https=)
AU (1) AU2022213335A1 (https=)
BR (1) BR112023014825A2 (https=)
CA (1) CA3173656A1 (https=)
IL (1) IL304402A (https=)
MX (1) MX2023008746A (https=)
TW (1) TW202245806A (https=)
WO (1) WO2022164941A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
WO2024211746A1 (en) * 2023-04-06 2024-10-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Treatment of autoimmune diseases and cancer with protease inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144460A1 (en) * 2017-01-31 2018-08-09 Loreal Topcoat for permanent lip make up
WO2019200005A1 (en) * 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
WO2020117966A1 (en) * 2018-12-05 2020-06-11 Atea Pharmaceuticals, Inc. Highly active drug combination for treatment of hepatitis c virus
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144460A1 (en) * 2017-01-31 2018-08-09 Loreal Topcoat for permanent lip make up
WO2019200005A1 (en) * 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
WO2020117966A1 (en) * 2018-12-05 2020-06-11 Atea Pharmaceuticals, Inc. Highly active drug combination for treatment of hepatitis c virus
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Also Published As

Publication number Publication date
KR20230135635A (ko) 2023-09-25
US20230365611A1 (en) 2023-11-16
TW202245806A (zh) 2022-12-01
EP4284389A4 (en) 2025-04-16
EP4284389A1 (en) 2023-12-06
AU2022213335A1 (en) 2023-07-27
WO2022164941A1 (en) 2022-08-04
MX2023008746A (es) 2023-08-01
CN116744939A (zh) 2023-09-12
US20260035404A1 (en) 2026-02-05
IL304402A (en) 2023-09-01
CA3173656A1 (en) 2022-08-04
BR112023014825A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
US20260035404A1 (en) Advantageous morphic form of at-527 hemi-sulfate salt
JP7542888B2 (ja) Ｃｏｖｉｄ－１９に対する高活性化合物
JP5128948B2 (ja) 癌の治療のための新規な薬剤組成物
JP2024513571A (ja) 抗ウイルス剤としてのチオヌクレオシド
EP3061452B1 (en) Icaritin for use in preventing or treating hematocytopenia
TW202033515A (zh) 用於治療c型肝炎病毒之高活性藥物組合
JP2018529777A (ja) Ｈｃｖの治療に対する併用療法レジメン
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
KR20240022574A (ko) 유리한 항-hcv 조합 요법
CN118615305A (zh) 3β-O-Glc-DM在抑制或治疗耐药型胶质母细胞瘤中的应用
HK40061232B (en) Highly active compounds against covid-19
HK40036124A (en) Methods of using dipivefrin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310